This was successfully posted to your pofile.
This box will close automatically in a few seconds. Close this window
We don't have an e-mail address on file for you. To use AAFP Connection, you must have an e-mail address in our records. Click Here
Diabetes Drug Poses Cancer, Pancreatitis Risks
Manufacturer Alerting Physicians to Safety Issues With Liraglutide
By News Staff
Liraglutide is indicated as an adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes mellitus. In its letter, Novo Nordisk emphasized that the drug is not recommended as a first-line therapy for patients who have inadequate glycemic control with diet and exercise because of the potential risk of thyroid C-cell tumors, including medullary thyroid carcinoma, or MTC, and the increased risk of acute pancreatitis.
The manufacturer provided the following information for physicians related to thyroid C-cell tumors:
- Liraglutide causes dose-dependent and treatment-duration-dependent thyroid C-cell tumors at clinically relevant exposures in both genders of rats and mice. It is unknown whether the drug causes thyroid C-cell tumors, including MTC, in humans. Human relevance could not be ruled out by clinical or nonclinical studies.
- Liraglutide is contraindicated in patients with a personal or family history of MTC and in patients with multiple endocrine neoplasia syndrome type 2.
- Patients with thyroid nodules noted on physical examination or neck imaging obtained for other reasons should be referred to an endocrinologist for further evaluation.
- Although routine monitoring of serum calcitonin is of uncertain value in patients treated with liraglutide, if serum calcitonin is measured and found to be elevated, the patient should be referred to an endocrinologist for further evaluation.
Physicians are encouraged to report adverse events associated with the medication to the FDA's MedWatch program.
Novo Nordisk said it will be monitoring cancer registries to identify any increase in the incidence of MTC related to the introduction of liraglutide into the U.S. marketplace. All cases of MTC, regardless of potential association with any drug treatment, should be reported to the appropriate state cancer registry, the manufacturer said.
Access to Rosiglitazone to Be Restricted, Says FDA
Physicians, Patients Required to Enroll in REMS Program
More From AAFP
AFP By Topic: Type 2 Diabetes
(some material available to Members/Paid Subscribers only)
Prescribing Information for Liraglutide (26-page PDF; About PDFs)
CDC: Diabetes Public Health Resource